NEW YORK, NY / ACCESSWIRE / March 26, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASDAQ:GOSS). Investors who purchased Gossamer securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/goss.
The investigation concerns whether Gossamer and certain of its officers and/or directors have violated federal securities laws.
Gossamer's most advanced product is its GB001 drug, a DP2 antagonist, in development to treat asthma. In February 2019, Gossamer conducted its initial public offering ("IPO"), issuing approximately 19.8 million shares of common stock priced at $19.00 per share. Then, on December 16, 2019, Novartis announced that it was terminating the development of its DP2 antagonist for asthma after it failed a pair of phase 3 clinical trials. Following this announcement, Gossamer's stock price fell $9.41 per share, or 37.09%, to close at $15.96 per share on December 16, 2019.
If you are aware of any facts relating to this investigation, or purchased Gossamer shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/goss. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC